NEW YORK (GenomeWeb News) — MedImmune yesterday said it has licensed its reverse genetics intellectual property to Novartis to help the drug maker develop new influenza vaccine strains.
 
Terms of the deal call for MedImmune to receive an upfront payment from Novartis, as well as the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.